Erik Engelson

Erik Engelson is an accomplished executive and strategic leader in the healthcare sector, currently serving as CEO of Dragon Vascular, Inc., where the focus is on innovative blood clot extraction technologies for stroke intervention. Engelson holds various positions including Strategic Advisor at Venova Medical, Board Observer at Inquis Medical, Inc., and Chairman at Alimetry. Previous roles include President & CEO of Lucira Health, which is now part of Pfizer, and Chairman of ARANZ Medical, Inc. Engelson has also contributed as a Board Member at Invicta Medical and Neptune Medical, and as a Venture Partner at ShangBay Capital, specializing in healthcare venture investments. Engelson's educational background includes a Master's degree in Bioengineering and a Bachelor's degree in Microbiology from UC San Diego, as well as an MBA from Stanford University Graduate School of Business.